SHASUNPHAR

Shasun Chemicals And Drugs Ltd. has informed the Exchange that the Board, at its meeting held on June 27, 2009 has not recommended any dividend for current year due to losses.

Shasun Chemicals And Drugs Ltd. has informed the Exchange that Mr. Dinesh Bhutda has been appointed as Company Secretary w.e.f. April 01, 2009 as decided in the Board Meeting held on January 22, 2009.

Shasun Chemicals And Drugs Ltd. has informed the Exchange that Notice pursuant Section 192A of the Companies Act, 1956, containing Resolution relating to remuneration payable to Mr N Govindarajan Narayanan, CEO & Managing Director for the financial year ended March 31, 2009, in the absence of adequate profit. Further as per the Report dated April 10, 2009, submitted by Mrs. B. Chandra Scrutinizer appointed for conducting the process of voting by Postal Ballot, the above mentioned Resolution in the said Notice have been approved by the Members of the Company by requisite majority. A copy of the

Shasun Chemicals And Drugs Ltd. has informed the Exchange that the company will be publishing Audited Results, for the financial year 2008-09, before June 2009 and therefore unaudited results for the quarter ending March 31, 2009 will not be published by the company.

Shasun Chemicals And Drugs Ltd. has informed the Exchange that pursuant to section 192A of the Companies Act, 1956 read with the Companies (Passing of the Resolution by Postal Ballot) Rules, 2001, for the consent of the shareholders of the company for the following : Special Resolution pursuant to the provision of Section 198, 269,309 and 310 read with Schedule XIII of Companies Act 1956. The Board of Directors have appointed Mrs. Chandra B. Practicing Company Secretary as Scrutinizer for conducting the Postal Ballot voting process in fair and transparent manner. The duly completed postal bal

Shasun Chemicals And Drugs Ltd. has submitted to the Exchange the details of shares pledged by the promoter in terms of Regulation 8A(4) of SEBI (Substantial Acquisition of shares and takeovers Regulations, 1997). The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Shasun_Pledge_06022009.zip target=NEW> For more details click here.</a>

Shasun Chemicals And Drugs Ltd. has informed the Exchange regarding a press release dated October 24, 2008, titled "Shasun Chemicals Q2FY09 revenues up 5% at Rs. 127 crore". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Shasun_PR_24102008.zip target=NEW> For more details click here.</a>

Shasun Chemicals And Drugs Ltd. has informed the Exchange regarding a press release dated July 26, 2008, titled "Shasun Chemicals posts Standalone Revenue of Rs. 103.23 crores in Q1FY09". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Shasun_Pr_26072008.zip target=NEW> For more details click here.</a>

Shasun Chemicals And Drugs Ltd. has informed the Exchange that the Board of Directors at their meeting held on June 04, 2008 have decided to close the Share Transfer Books of the Company from July 19, 2008 to July 26, 2008 - both days inclusive, for the purpose of AGM to be held on July 26, 2008 and dividend of Rs.1.00 per share.

Shasun Chemicals And Drugs Ltd. has informed the Exchange vide its letter dated June 05, 2008, regarding a press release dated June 04, 2008, titled "Shasun Chemicals FY08 Consolidated Revenue up 10.77% at Rs.887.20 crore; Board Recommends Final Dividend of 50%". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Shasun_PR_05062008.zip target=NEW> For more details click here.</a>

Shasun Chemicals And Drugs Ltd. has informed the Exchange that the Board of Directors of the Company at its meeting held on June 04, 2008 has recommended a dividend of 50% (Rs.1 per share) on the equity share of Rs.2/- each.

Shasun Chemicals And Drugs Ltd. has informed the Exchange that : "We will be publishing Audited Results, for the financial Year 2007-2008, before June 2008 and therefore unaudited Results for the Quarter ending 31st March 2008 will not be published by us".

Shasun Chemicals And Drugs Ltd. has informed the Exchange regarding a media release titled "Icra has assigned an A1+ rating to the Rs.878 Million sanctioned bank limits for Fund Based facilities and to the Rs.200 Million sanctioned bank limits for Non Fund Based facilities of Shasun Chemicals & Drugs Ltd (SCDL). This is the highest-creditquality rating assigned by ICRA to short-term debt instruments". A copy of the media release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements)

Shasun Chemicals And Drugs Ltd. has informed the Exchange regarding a media release dated February 27, 2008, titled "Shasun signs technology licensing agreement with Merck & Co., Inc". A copy of the media release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Shasun_MR_27022008.zip target=NEW> For more details click here.</a>

Shasun Chemicals And Drugs Ltd. has informed the Exchange regarding a media release dated January 28, 2008, titled "Shasun Chemicals to set up new facilities in Piscataway, US".A copy of the media release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Shasun_MR_28012008.zip target=NEW> For more details click here.</a>

Shasun Chemicals And Drugs Ltd. has informed the Exchange that "This is with reference to the article in the Economic Times dated October 18, 2007, stating Reliance, Mylan & Ranbaxy eye Shasun's API biz'. We would like to bring to notice that Shasun is not looking to sell off any part of its business. The news items are based on mere rumours and are hence speculative in nature".

Shasun Chemicals And Drugs Ltd. had informed the Exchange that Shasun Pharma Solutions Ltd a wholly owned UK Subsidiary of Shasun Chemicals And Drugs Limited, has entered into a non-exclusive licensing agreement with H-Lundback A/S a research based Danish Company. Further, the company had submitted to the Exchange the details of the same. The company has now informed the Exchange that: "In para "3" of our enclosure Dr Michel Spagnol - Vice President of Shasun Pharma Solutions Limited has been inadvertently mentioned as Dr Michel Spagnol of H Lundback A/S".

Shasun Chemicals And Drugs Ltd. has informed the Exchange that: "Shasun Pharma Solutions Ltd a wholly owned UK Subsidiary of Shasun Chemicals And Drugs Limited, has entered into a non-exclusive licensing agreement with H-Lundback A/S a research based Danish Company". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Shasun_Det1_10072007.zip target=NEW> For more details click here.</a>

Shasun Chemicals And Drugs Ltd. has informed the Exchange that the Board of Directors at their meeting held on May 29, 2007 have decided to close the Share Transfer Books of the Company during the following period for the purpose of Annual General Meeting (to be held on July 24, 2007) and dividend (Rs. 0.90 per share) : July 17, 2007 to July 24 ,2007 - both days inclusive.

Shasun Chemicals And Drugs Ltd. has informed the Exchange that the Board of Directors at its meeting held on May 29, 2007 has recommended a final dividend of Rs.0.90 per share which makes the total dividend to Rs.1.70 per share for the year.

Shasun Chemicals And Drugs Ltd. has informed the Exchange that the Company shall publish Audited Financial Results within a period of 3 month for the year ended on March 31, 2007 i.e. on or before June 30, 2007.

Shasun Chemicals And Drugs Ltd. has informed the Exchange that "This in is respect to the media article : 'Ranbaxy says no plans to issue US shares' that appeared in The Economic Times of Tuesday, 20th February 2007. Shasun Chemicals and Drugs has been erroneously cited as being in the race to buy Ranbaxy's unit in Ireland. The Company would like to clarify that the news item is speculative and we deny any such development at the moment. We re-iterate that as part of the Listing Agreement, any corporate development would be first intimated to the stock exchanges."

Shasun Chemicals And Drugs Ltd. has informed the Exchange that the Board at its meeting held on 18.01.2007 declared the interim dividend of Rs. 0.80 per share. The Record date for this purpose be fixed as February 06, 2007.

Shasun Chemicals And Drugs Ltd. has informed the Exchange on January 19,2007 that: "Shasun Pharma Solutions Ltd (SPSL) UK as wholly owned subsidiary of Shasun Chemicals and Drugs Limited (SCDL), India announced today that Mr. Nick Green, CEO & MD of SPSL, would be leaving the company effective Jan 18,2007. Board of SCDL would like to thank Mr. Nick Green for his contribution and wish him success for future. In the interim, Mr.N.Govindarajan, CEO & MD of SCDL will assume additional responsibility of CEO and MD of SPSL".

Shasun Chemicals And Drugs Ltd. has informed the Exchange that the Board at its meeting held on January 18,2007 has declared interim dividend of Rs.0.80 per share.

Shasun Chemicals And Drugs Ltd. has informed the Exchange that the Board of Directors of the Company have, at their meeting held on October 19, 2006 decided to issue and allot 22,50,000 warrants on preferential basis to promoters / promoter Group(s), with each warrant convertible into one equity shares of the company as per the SEBI Guidelines and subject to the approval of the Share holders.

Shasun Chemicals And Drugs Ltd. has submitted to the Exchange a text of disclosure made by the company to analysts during their visit to Shasun Pharma Solutions Limited. U. K. - a subsidiary of Shasun Chemicals and Drugs Limited. The details of same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).<a href=/content/corporate/Shasun_260906.zip target=NEW> For more details click here.</a>

Shasun Chemicals And Drugs Ltd. has informed the Exchange that the Board of Directors at their meeting held on May 25,2006 have decided to close the Share Transfer Books of the Company during the following period for the purpose of AGM (to be held on July 21,2006) and dividend (Rs. 1.70 per share) : July 14,2006 to July 21,2006 - both days inclusive.

Shasun Chemicals And Drugs Ltd. has informed the Exchange that SBI Mutual Fund has sold 818488 shares aggregating to 1.7036% of the total share capital of Shasun Chemicals & Drugs Ltd. on April 07, 2006. The mode of sale is through Open Market and the shareholding of SBI Mutual Fund after the said sale is 2488267 shares aggregating to 5.1791% of the total share capital of Shasun Chemicals & Drugs Ltd.

Shasun Chemicals And Drugs Ltd. has informed the Exchange that the Board of Directors of the Company, have, at their meeting held on May 25, 2006, decided to issue and allot 22,50,000 warrants on preferential basis to promoters / promoter Group(s), with each warrant convertible into one equity share of the company as per the SEBI Guidelines and subject to the approval of the Shareholders.

Shasun Chemicals And Drugs Ltd. has informed the Exchange that the BODs of the Company in their meeting held on May 25, 2006 has recommended a Final Dividend of Rs.1.70 per share.

Shasun Chemicals And Drugs Ltd. has informed the Exchange that the Company on March 31, 2006 completed its acquisition of the Pharmaceutical Custom Synthesis business of the Rhodia group. In this connection, the Company has submitted to the Exchange the public announcement dated, March 31, 2006, titled, "Shasun Chemicals acquires Rhodia Pharma custom synthesis business.". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Shasun Chemicals And Drugs Ltd. has informed the Exchange that the company has received the approval from Medicines and Healthcare products Regulatory Agency (MHRA), UK for its WHO-CGMP Formulation facility manufacturing Oral Solid Dosage forms (Tablets and Capsules) for the bulk Tablets Packing. With this approval, Shasun's products from its brand new formulation facility could be sold on commercial basis to UK and European Countries.

Shasun Chemicals And Drugs Ltd. has informed the Exchange regarding a public announcement dated January 06, 2006, titled "SHASUN CHEMICALS & DRUGS LTD SIGNS A LETTER OF INTENT WITH RHODIA -WITH A VIEW TO ACQUIRE ITS PHARMACEUTICAL CUSTOM SYNTHESIS BUSINESS". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Clarification of News : The media had reports that Shasun Chemicals and Drugs Limited may acquire a plant in Europe in contract manufacturing space. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Shasun Chemicals and Drugs Ltd. has vide its letter inter-alia stated, "We would like to clarify that as part of our inorganic growth strategy, we are in talks with various companies at different occasions. These are prel

Shasun Chemicals And Drugs Ltd. has informed the Exchange that SBI Mutual Fund has acquired 201035 shares aggregating to 2.20% of the total share capital of Shasun Chemicals & Drugs Ltd. on August 18, 2005. The mode of acquisition is through Open Market and the shareholding of SBI Mutual Fund after the said acquisition is 661351 shares aggregating to 7.22% of the total share capital of Shasun Chemicals & Drugs Ltd.

Shasun Chemicals And Drugs Ltd. has informed the Exchange that the BODs at its meeting held on July 23, 2005 fixed the Record Date as August 26, 2005 for split of shares from Nominal value of Rs.10/- per equity share to Rs.2/- per equity share approved at its AGM held on July 23, 2005.

Shasun Chemicals And Drugs Ltd. has informed the Exchange that the Company is seeking, the approval of the members, to approve the split of shares of the nominal vlaue of Rs.10/- per share to Rs.2/- per share at the ensuing AGM to be held on July 23, 2005.

Shasun Chemicals And Drugs Ltd. has informed the Exchange that SBI Mutual Fund have acquired 27,878 shares aggregating to 0.30% of the total paid up capital of Shasun Chemicals & Drugs Ltd. on June 15, 2005. The mode of acquisition is through Open Market and the shareholding of SBI Mutual Fund after the said acquisition is 460,316 shares aggregating to 5.03% of the total paid up capital of Shasun Chemicals & Drugs Ltd.

SBI Mutual Fund has informed the Exchange that they, under their various schemes, have acquired 27,878 shares aggregating to 0.3% of the total paid up capital of Shasun Chemicals & Drugs Ltd. on June 15, 2005. The mode of acquisition is Market Purchase and the shareholding of SBI Mutual Fund under its various schemes after the said acquisition is 460,316 shares aggregating to 5.03% of the total paid up capital of Shasun Chemicals & Drugs Ltd. The schemewise details shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Serve

Shasun Chemicals And Drugs Ltd. has informed the Exchange that GMO Emerging Market Fund has sold 2,31,956 shares aggregating to 2.53% of the total paid up capital of Shasun Chemicals And Drugs Limited on May 25, 2005. The mode of sale is through Secondary Market and the shareholding of GMO Emerging Market Fund after the said sale is 6,78,044 shares aggregating to 7.40% of the total paid up capital of Shasun Chemicals And Drugs Limited.

Shasun Chemicals And Drugs Ltd. has informed the Exchange that the Board of Directors at their meeting held on May 26, 2005 have decided to close the Share Transfer Books of the company from July 15, 2005 to July 23, 2005 (both days inclusive) for the purpose of AGM to be held on July 23, 2005 and dividend @ Rs.7.50 per share.

Shasun Chemicals And Drugs Ltd. has informed the Exchange that company has entered into a exclusive agreement with New-Jersey-based Alpharma Inc. for marketing its select generic formulations in US and Europe. Under this agreement, Shasun will develop and manufacture 10 generic formulations in specific dosage forms and strengths for exclusive distribution and marketing by Alpharma in the US and Europe. These ten oral formulations fall under speciality, chronic therapeutic segments such as cardio-vascular (CVS) and central nervous system (CNS) categories. Under the agreement, Alpharma would pro

Shasun Chemicals And Drugs Ltd. has informed the Exchange that following points were recommended in the Board meeting held on May 26, 2005:- 1.The Board has approved to increase FII Limits to 30% in Equity Share Capital subject to approval from Shareholders and Regulatory Bodies. 2.The Board has recommended to subdivide the face value of the equity shares from Rs. 10 to Rs. 2 subject to approval from Shareholders and Regulatory Bodies.

Shasun Chemicals And Drugs Ltd. has informed the Exchange that the Board of Directors at its meeting held on May 26, 2005 has recommended Final dividend of Rs.7.50 per share.

Shasun Chemicals And Drugs Ltd. has informed the Exchange that the board in its meeting held on May 26,2005 has :1) Approved to increase FII limits to 30% in equity share capital subject to approval from regulatory bodies.2)Recommended to subdivide the face value of the equity shares from Rs.10 to Rs.2 subject to approval from shareholders and regulatory bodies, if any.

Shasun Chemicals And Drugs Ltd. has informed the Exchange that the Company has signed a manufacturing and supply agreement for a pharmaceutical intermediate for a generic drug with Codexis Inc., USA, which is a privately held Biosciences company applying proprietary protein and strain engineering technologies to create novel process development solutions for efficient, cost-effective and environmentally friendly pharmaceutical manufacturing from 2002. Under terms of the agreement, Shasun will manufacture the pharmaceutical compound and Codexis will market the product worldwide to the generic p

Shasun Chemicals And Drugs Ltd. has informed the Exchange that the company has entered into a collaboration agreement with Glenmark Pharmaceuticals Ltd., for filing and marketing of thirteen generic pharmaceutical products for the US market. The product list includes a mixture of off-patent and patent-protected molecules. Under the agreement, Shasun will develop and license to Glenmark, thirteen generic products. Glenmark in turn, will be responsible for filing the ANDAs and obtaining regulatory approval in the US market. Upon approval, Glenmark's US subsidiary, Glenmark Pharmaceutical Inc., w

Shasun Chemicals And Drugs Ltd. has informed the Exchange that despite the tragic incident of Tsunami neither of the company's manufacturing plants in Pondicherry and Cuddalore have been affected. However operations were stopped for a day on December 26, 2004 as a precautionary measure and since resumed from December 27,2004.

Shasun Chemicals And Drugs Ltd. has informed the Exchange that the company has been receiving enquiries from various sources directed at Merck's worldwide withdrawal of its VIOXX (Rofecoxib) and its impact on the status of the Company's DMF filing for Rofecoxib. In this regard the company has clarified that this action of Merck is not anticipated to have any material impact on the operational performance of Shasun.